uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QURE uniQure NV

Market Closed 12-19 16:00:00 EST

23.99

+0.06

+0.25%

盘后24.27

+0.28+1.17%

19:50 EST

High25.40	Low23.10	Vol7.29M
Open23.77	D1 Closing23.93	Amplitude9.61%
Mkt Cap1.49B	Tradable Cap974.86M	Total Shares62.29M
T/O176.27M	T/O Rate17.93%	Tradable Shares40.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QURE","market":"US","secType":"STK","nameCN":"uniQure NV","latestPrice":23.99,"timestamp":1766178000000,"preClose":23.93,"halted":0,"volume":7286419,"hourTrading":{"tag":"盘后","latestPrice":24.27,"preClose":23.99,"latestTime":"19:50 EST","volume":656465,"amount":15749395.2616,"timestamp":1766191806728},"delay":0,"floatShares":40636300,"shares":62291663,"eps":-4.344329,"marketStatus":"Market Closed","change":0.06,"latestTime":"12-19 16:00:00 EST","open":23.765,"high":25.4,"low":23.1,"amount":176273114.025771,"amplitude":0.096114,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.344329,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766394000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1391576400000,"exchange":"NASDAQ","adjPreClose":23.93,"preHourTrading":{"tag":"盘前","latestPrice":23.65,"preClose":23.93,"latestTime":"09:29 EST","volume":2552,"amount":60417.57920000001,"timestamp":1766154599999},"postHourTrading":{"tag":"盘后","latestPrice":24.27,"preClose":23.99,"latestTime":"19:50 EST","volume":656465,"amount":15749395.2616,"timestamp":1766191806728},"volumeRatio":1.782738,"impliedVol":1.1136,"impliedVolPercentile":0.676},"requestUrl":"/m/hq/s/QURE","defaultTab":"news","newsList":[{"id":"2592924426","title":"Does uniQure (QURE) FDA Feedback on AMT-130 Reframe Its Risk, Funding and Strategy Profile?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592924426","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592924426?lang=en_us&edition=fundamental","pubTime":"2025-12-18 09:34","pubTimestamp":1766021682,"startTime":"0","endTime":"0","summary":"In early December 2025, uniQure reported that final FDA meeting minutes indicated Phase I/II data for its Huntington's gene therapy AMT-130 are currently unlikely to provide the primary evidence needed for a Biologics License Application, prompting the company to seek a follow-up meeting in early 2026.\nThis feedback raises questions about trial design, endpoint robustness, and the potential need for additional studies, sharpening focus on uniQure’s regulatory pathway and funding capacity for...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/does-uniqure-qure-fda-feedback-on-amt-130-reframe-its-risk-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/does-uniqure-qure-fda-feedback-on-amt-130-reframe-its-risk-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4219","LU0889565916.HKD","AMT","BK4084","BK4581","BK4554","LU0109394709.USD","BK4534","QURE","LU0320765992.SGD","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2592932207","title":"uniQure call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2592932207","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592932207?lang=en_us&edition=fundamental","pubTime":"2025-12-17 04:05","pubTimestamp":1765915512,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in uniQure (QURE) with 4,979 calls trading, 1.1x expected, and implied vol increasing almost 4 points to 84.35%. Jan-2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0109394709.USD","LU0889565916.HKD","QURE","LU0320765992.SGD"],"gpt_icon":0},{"id":"2592939206","title":"What's Going On With uniQure Stock On Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592939206","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592939206?lang=en_us&edition=fundamental","pubTime":"2025-12-17 01:17","pubTimestamp":1765905420,"startTime":"0","endTime":"0","summary":"uniQure shares slid nearly 31% in a month as the FDA raised concerns over whether AMT-130 Phase 1/2 data can support approval.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/16/Indecision-In-The-Stock-Or-Crypto-Market.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/16/Indecision-In-The-Stock-Or-Crypto-Market.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/biotech/25/12/49428299/whats-going-on-with-uniqure-stock-on-tuesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/biotech/25/12/49428299/whats-going-on-with-uniqure-stock-on-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["QURE","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","BK4139"],"gpt_icon":0},{"id":"2589831064","title":"uniQure Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2589831064","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589831064?lang=en_us&edition=fundamental","pubTime":"2025-12-05 02:52","pubTimestamp":1764874320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QURE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 04, 2025 13:52 ET (18:52 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0889565916.HKD","BK4139","QURE","LU0109394709.USD"],"gpt_icon":0},{"id":"2589831281","title":"Why uniQure Stock Is Trading Lower After FDA Meeting Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2589831281","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589831281?lang=en_us&edition=fundamental","pubTime":"2025-12-05 02:30","pubTimestamp":1764873000,"startTime":"0","endTime":"0","summary":"The gene therapy company received final meeting minutes from the FDA regarding a pre-Biologics License Application for AMT-130","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/04/Health-care--Lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/04/Health-care--Lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49216662/why-uniqure-stock-is-trading-lower-after-fda-meeting-update","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49216662/why-uniqure-stock-is-trading-lower-after-fda-meeting-update","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4550","BK4139","LU0238689110.USD","LU0942090050.USD","IE00B1XK9C88.USD","LU1035775433.USD","LU1236620750.USD","LU0109394709.USD","LU1496350171.SGD","LU1778281490.HKD","LU1551013425.SGD","LU2756315318.SGD","LU0320765646.SGD","BK4581","LU2361044949.HKD","BK4567","LU0689472784.USD","LU1674673428.USD","HD","IE00BWXC8680.SGD","LU1093756168.USD","LU0820562030.AUD","BK4534","LU1093756325.SGD","QURE","BK4083","BK4504","LU1069344957.HKD","LU0820561909.HKD","LU0234572021.USD","LU0354030438.USD","LU0820561818.USD","LU0823434740.USD","LU1162221912.USD","LU0889565916.HKD","LU1551013342.USD","BK4533","IE00BKVL7J92.USD","LU0354030511.USD","LU1989772840.SGD","IE00BSNM7G36.USD","LU1674673691.USD","LU1914381329.SGD","LU1989772923.USD","LU2756315664.SGD","LU0079474960.USD","LU0868494708.USD","LU0823434583.USD","LU2461242641.AUD","LU2361044865.SGD"],"gpt_icon":0},{"id":"2588887251","title":"UniQure Shares Drop After More Negative News From FDA on Huntington's Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2588887251","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588887251?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:02","pubTimestamp":1764856920,"startTime":"0","endTime":"0","summary":"UniQure shares fell Thursday after the gene therapy company said its Huntington's disease drug hit more regulatory roadblocks.Shares of the Lexington, Mass., company fell 15% early Thursday, to $21.25, though the stock is up 44% year-to-date.UniQure said the U.S. Food and Drug Administration said data submitted from the Phase I and Phase II studies of its drug AMT-130 are unlikely to provide the primary evidence to support a biologics license application submission. A BLA is a formal request to introduce a biologic product and the FDA reviews it to determine safety and performance before full authorization.UniQure said it's carefully evaluating the feedback and will urgently request a follow-up meeting with the FDA for the first quarter of 2026.\"We are committed to collaborating with the FDA to advance AMT-130 to patients and their families as rapidly as possible,\" said Chief Executive Matt Kapusta.AMT-130 is being developed to slow the progression of Huntington's disease. The FDA prev","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"UniQure Shares Drop After More Negative News From FDA on Huntington's Disease Drug","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","QURE","LU0320765992.SGD","BK4139","LU0889565916.HKD"],"gpt_icon":0},{"id":"2588881202","title":"uniQure Seeks US FDA Follow-Up Meeting After Being Told Data Do Not Support BLA Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2588881202","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588881202?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:40","pubTimestamp":1764852023,"startTime":"0","endTime":"0","summary":"uniQure  said Thursday that it will \"urgently\" seek a follow-up\" meeting with the US Food and Drug Administration after the regulator said phase 1/2  studies of AMT-130 data are now unlikely to support a Biologics License Application submission.AMT-130 is an investigational gene therapy intended to treat patients with Huntington's disease, the company said.uniQure said it is evaluating the feedback and is looking to meet with the FDA in Q1.Shares of uniQure were down 19% in recent Thursday premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QURE","BK4139","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":1},{"id":"2586267979","title":"uniQure put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2586267979","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586267979?lang=en_us&edition=fundamental","pubTime":"2025-11-27 04:15","pubTimestamp":1764188114,"startTime":"0","endTime":"0","summary":"Bearish flow noted in uniQure (QURE) with 6,020 puts trading, or 2x expected. Most active are Dec-25 20 puts and Dec-25 15 puts, with total volume ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-put-volume-heavy-and-directionally-bearish-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-put-volume-heavy-and-directionally-bearish-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LU0889565916.HKD","QURE","LU0109394709.USD","BK4139"],"gpt_icon":0},{"id":"2585167595","title":"Biotech Reawakens: Policy Clarity, Breakthrough Data and a Surge in M&A","url":"https://stock-news.laohu8.com/highlight/detail?id=2585167595","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585167595?lang=en_us&edition=fundamental","pubTime":"2025-11-21 10:52","pubTimestamp":1763693545,"startTime":"0","endTime":"0","summary":"Sentiment toward pharmaceuticals—both emerging biotech and large-cap pharma—has shifted meaningfully since we last wrote at the end of FY25. Concerns around US tariff risk and “Most Favoured Nation”  pricing dominated headlines in April, but these issues have since been largely neutralised. As policy uncertainty has cleared, investors have returned their focus to fundamentals.From 30 June to 31 October 2025, the S&P Biotech Index rose more than 30%. Over the same period, HB Biotechnology portfolios delivered a 63% return, driven by multiple outstanding clinical readouts and two strategic takeovers of portfolio companies.Despite this global strength, the ASX healthcare sector has lagged , led by the ongoing weakness in ASX: CSL—once again underscoring the need for a global, diversified approach to healthcare investing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/biotech-reawakens-policy-clarity-breakthrough-data-and-a-surge-in-m-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/biotech-reawakens-policy-clarity-breakthrough-data-and-a-surge-in-m-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK4559","QURE","QID","VRNA","PFE","BK4532","PSQ","CSL.AU","SQQQ","LU1037948897.HKD","LU0098860793.USD","LU1116320901.HKD","MRK","USJW.SI","LU2089984988.USD","QLD","BK4505","CELC","USAW.SI","TSYW.SI","LU1430594728.SGD","IE000M9KFDE8.USD","LU0265550359.USD","LU0289739699.SGD","SG9999014559.SGD","LU2023250504.SGD","NVS","IE00BN8TJ469.HKD","RNA","TQQQ","VIGL","LU0238689110.USD","LU2324357040.USD","IE00BSNM7G36.USD","LU0861579265.USD","SGXZ57979304.SGD","REPL","NQmain","LU0985320562.USD","LU1057294990.SGD","IE00B19Z3B42.SGD","LU1929549753.HKD",".IXIC","MNQmain","LU1934455277.USD","BK7067","NVIW.SI","LU0265550946.USD","LU1934455194.USD"],"gpt_icon":1},{"id":"2584896174","title":"Do Rising Losses at uniQure (QURE) Reflect Strategic Investment or Escalating Cost Pressure?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584896174","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584896174?lang=en_us&edition=fundamental","pubTime":"2025-11-19 03:28","pubTimestamp":1763494114,"startTime":"0","endTime":"0","summary":"uniQure N.V. reported its third quarter 2025 financial results on November 10, with revenue rising to US$3.7 million from US$2.29 million a year earlier, accompanied by a net loss of US$80.53 million.\nAn interesting insight from the announcement is that, despite higher quarterly revenue, the company’s losses deepened compared to the previous year, pointing to ongoing cost pressures or investment needs.\nWe’ll now explore how uniQure’s widening quarterly losses and revenue changes could impact...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/do-rising-losses-at-uniqure-qure-reflect-strategic-investmen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/do-rising-losses-at-uniqure-qure-reflect-strategic-investmen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","QURE","BK4139"],"gpt_icon":0},{"id":"2583582821","title":"A Deep Dive into uniQure (QURE) Valuation After FDA Uncertainty Shakes Huntington’s Disease Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2583582821","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583582821?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:28","pubTimestamp":1762982911,"startTime":"0","endTime":"0","summary":"uniQure (NasdaqGS:QURE) shares experienced a sharp reaction after the FDA unexpectedly indicated that Phase I/II data for AMT-130 in Huntington’s disease may not support the company’s Biologics License Application. This change introduces new regulatory uncertainty for investors.\nSee our latest analysis for uniQure.\nThis regulatory curveball comes after a volatile year for uniQure. Enthusiasm from promising clinical trial results quickly turned to caution as investors reassessed the timeline...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-deep-dive-into-uniqure-qure-valuation-after-fda-uncertaint","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-deep-dive-into-uniqure-qure-valuation-after-fda-uncertaint","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK4139","QURE"],"gpt_icon":0},{"id":"1138163270","title":"Stock Track | uniQure NV Soars 5.71% Pre-market on Bullish Analyst Ratings","url":"https://stock-news.laohu8.com/highlight/detail?id=1138163270","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138163270?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:03","pubTimestamp":1762952608,"startTime":"0","endTime":"0","summary":"uniQure NV (QURE) shares are surging 5.71% in pre-market trading on Wednesday, building on the previous day's gains. The biotechnology company's stock is attracting investor attention following...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["QURE"],"gpt_icon":0},{"id":"2582375192","title":"uniQure (QURE) Gets a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375192","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375192?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:19","pubTimestamp":1762949968,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Yanan Zhu maintained a Buy rating on uniQure today and set a price target of $60.00. Zhu covers the Healthcare sector, focusing...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/uniqure-qure-gets-a-buy-from-wells-fargo-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/uniqure-qure-gets-a-buy-from-wells-fargo-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1035773651.USD","IE000M9KFDE8.USD","LU0267386448.USD","LU1506573853.SGD","LU0889565916.HKD","LU0251131958.USD","LU0477156953.USD","LU0310799852.SGD","BK4207","LU0052756011.USD","LU0211327993.USD","LU1267930490.SGD","BK4139","LU1267930227.SGD","IE00B7SZLL34.SGD","LU0320765489.SGD","LU0648001328.SGD","LU0683600562.USD","LU0787776722.HKD","LU0868494708.USD","LU2236285917.USD","XLV","LU0742534661.SGD","BK4559","LABU","LU0048573561.USD","LU0128525689.USD","LU0128525929.USD","LU0640476718.USD","LU1791807156.HKD","LU1814569148.SGD","LU0256863811.USD","XBI","LU0106831901.USD","LU1280957306.USD","LU2461242641.AUD","LU0310800965.SGD","QURE","LU0310800379.SGD","LU0175139822.USD","LU0251142724.SGD","LU1363072403.SGD","LU1069347547.HKD","IE0002270589.USD","LU0314106906.USD","LU1074936037.SGD","LU2361045086.USD","LU1267930573.SGD","BK4585","BK4504"],"gpt_icon":0},{"id":"1155974585","title":"Stock Track | uniQure NV Surges 5.32% as Chardan Capital Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1155974585","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155974585?lang=en_us&edition=fundamental","pubTime":"2025-11-12 09:24","pubTimestamp":1762910670,"startTime":"0","endTime":"0","summary":"uniQure NV (QURE) shares soared 5.32% in Tuesday's trading session, marking a significant uptick for the biotechnology company. The stock's impressive performance came amid broader market movements...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["QURE"],"gpt_icon":0},{"id":"2582270388","title":"uniQure Is Maintained at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2582270388","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582270388?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:28","pubTimestamp":1762810080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QURE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 16:28 ET (21:28 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0889565916.HKD","BK4139","QURE","LU0109394709.USD"],"gpt_icon":0},{"id":"2582414801","title":"uniQure price target lowered to $60 from $68 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2582414801","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582414801?lang=en_us&edition=fundamental","pubTime":"2025-11-11 02:30","pubTimestamp":1762799412,"startTime":"0","endTime":"0","summary":"Leerink lowered the firm’s price target on uniQure (QURE) to $60 from $68 and keeps an Outperform rating on the shares following quarterly results ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-price-target-lowered-to-60-from-68-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-price-target-lowered-to-60-from-68-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0889565916.HKD","QURE","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"1136462086","title":"uniQure Q3 2025 Earnings Call Summary and Q&A Highlights: Regulatory Challenges and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1136462086","media":"Earnings Call","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136462086?lang=en_us&edition=fundamental","pubTime":"2025-11-10 23:01","pubTimestamp":1762786877,"startTime":"0","endTime":"0","summary":"[Management View]Management reported a significant regulatory setback as the FDA no longer considers the Phase 1/2 external control data sufficient to support a BLA submission for AMT-130,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE"],"gpt_icon":0},{"id":"2582709588","title":"uniQure (QURE) Q3 2025 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2582709588","media":"Motley Fool Transcribing","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582709588?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:57","pubTimestamp":1762786670,"startTime":"0","endTime":"0","summary":"DateMonday, Nov. 10, 2025 at 8:30 a.m. ETCall participantsChief Executive Officer — Matthew KapustaChief Medical Officer — Walid Abi-SaabChief Commercial Officer — Kylie O'KeefeChief Financial Officer — Christian KlemtNeed a quote from a Motley Fool analyst?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_motley_transcript","url":"https://www.fool.com/earnings/call-transcripts/2025/11/10/uniqure-qure-q3-2025-earnings-call-transcript/","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/earnings/call-transcripts/2025/11/10/uniqure-qure-q3-2025-earnings-call-transcript/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_motley_transcript","symbols":["QURE"],"gpt_icon":0},{"id":"1104030441","title":"Stock Track | uniQure Plummets 8.82% as Q3 Results Miss Estimates and FDA Feedback Creates Uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=1104030441","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104030441?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:38","pubTimestamp":1762785485,"startTime":"0","endTime":"0","summary":"Shares of uniQure NV (QURE) plummeted 8.82% in pre-market trading on Monday, following the release of disappointing third-quarter financial results and uncertainty surrounding regulatory feedback for...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["QURE"],"gpt_icon":0},{"id":"1128434948","title":"Stock Track | uniQure Plummets 8.82% as Q3 Losses Widen and FDA Feedback Clouds AMT-130 Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=1128434948","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128434948?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:37","pubTimestamp":1762785470,"startTime":"0","endTime":"0","summary":"Shares of uniQure NV (QURE) plummeted 8.82% in pre-market trading on Monday following the release of disappointing third-quarter financial results and unexpected regulatory challenges for its key...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["QURE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.uniqure.com","stockEarnings":[{"period":"1week","weight":0.2296},{"period":"1month","weight":-0.1417},{"period":"3month","weight":0.7296},{"period":"6month","weight":0.6882},{"period":"1year","weight":0.5507},{"period":"ytd","weight":0.3584}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.","yearOnYearQuotes":[{"month":1,"riseRate":0.272727,"avgChangeRate":-0.00526},{"month":2,"riseRate":0.545455,"avgChangeRate":0.064233},{"month":3,"riseRate":0.25,"avgChangeRate":-0.054124},{"month":4,"riseRate":0.416667,"avgChangeRate":0.018299},{"month":5,"riseRate":0.666667,"avgChangeRate":0.042965},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.009437},{"month":7,"riseRate":0.25,"avgChangeRate":0.033059},{"month":8,"riseRate":0.5,"avgChangeRate":0.005984},{"month":9,"riseRate":0.25,"avgChangeRate":0.122705},{"month":10,"riseRate":0.5,"avgChangeRate":0.060394},{"month":11,"riseRate":0.75,"avgChangeRate":0.0616},{"month":12,"riseRate":0.25,"avgChangeRate":0.125316}],"exchange":"NASDAQ","name":"uniQure NV","nameEN":"uniQure NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"uniQure NV,QURE,uniQure NV股票,uniQure NV股票老虎,uniQure NV股票老虎国际,uniQure NV行情,uniQure NV股票行情,uniQure NV股价,uniQure NV股市,uniQure NV股票价格,uniQure NV股票交易,uniQure NV股票购买,uniQure NV股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction